CDT Equity (CDT)

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

O preço da ação CDT Equity Inc. Common Stock (CDT) pre-market hoje é de $ 1,18, refletindo uma movimentação +7,27% pre-market desde que o mercado last closed. A capitalização de mercado da empresa é de $ 2,72 mi, com um volume comercial diário de $ 13,50 mi ações. O preço de fechamento anterior foi $ 1,10.